What are bispecific antibodies?

 

In this week's video, Dr. Brian G.M. Durie explains how bispecific antibodies work and why they are being studied in clinical trials  to treat myeloma.

BOTTOM LINE:​
Bispecific antibodies are showing great promise in clinical trials.

Have a question? Submit it to AskDrDurie@myeloma.org

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org